STOCK TITAN
  1. Home
  2. Sec-filings
  3. EDIT
  4. [Form 4] Editas Medicine, Inc. Insider Trading Activity

Editas Medicine (EDIT) CEO logs automatic, tax-related share sale

Filing Impact
(Neutral)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Editas Medicine CEO O'Neill Gilmore Neil reported an automatic, tax-related share sale. On June 3, 2026, he sold 15,380 shares of common stock at a weighted average price of $2.7011 per share, leaving 248,313 shares owned directly.

The sale was executed under a durable automatic sales instruction plan adopted on April 13, 2022, and was made to cover tax withholding obligations from restricted stock units that vested on June 2, 2026. The footnote states this was not a discretionary trade by the CEO.

Positive

  • None.

Negative

  • None.
Insider O'Neill Gilmore Neil
Role CEO
Sold 15,380 shs ($42K)
Type Security Shares Price Value
Sale Common Stock 15,380 $2.7011 $42K
Holdings After Transaction: Common Stock — 248,313 shares (Direct, null)
Footnotes (1)
  1. Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on April 13, 2022, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on June 2, 2026. The sale does not represent a discretionary trade by the Reporting Person. This transaction was executed in multiple trades at prices ranging from $2.7010 to $2.7250. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request, to the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
Shares sold 15,380 shares Common Stock sale on June 3, 2026
Weighted average price $2.7011 per share Open-market sale price range $2.7010–$2.7250
Shares owned after transaction 248,313 shares Direct ownership following the June 3, 2026 sale
Plan adoption date April 13, 2022 Durable automatic sales instruction plan adoption
RSU vesting date June 2, 2026 Restricted stock units vesting that triggered tax withholding
durable automatic sales instruction plan financial
"Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on April 13, 2022"
restricted stock units financial
"represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
weighted average purchase price financial
"The price reported above reflects the weighted average purchase price"
The weighted average purchase price is the average cost per share you paid across multiple buys, calculated so larger purchases count more than smaller ones. Imagine buying apples at different prices: the overall price you effectively paid depends on how many apples you bought at each price. Investors use it to measure true cost basis, calculate gains or losses, decide when to sell, and manage taxes and portfolio performance.
open market or private transaction financial
"Sale in open market or private transaction"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
O'Neill Gilmore Neil
(Last)(First)(Middle)
C/O EDITAS MEDICINE, INC.
11 HURLEY ST.
(Street)
CAMBRIDGE MASSACHUSETTS 02141
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Editas Medicine, Inc. [ EDIT ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
CEO
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/03/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/03/2026S(1)15,380D$2.7011(2)248,313D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on April 13, 2022, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on June 2, 2026. The sale does not represent a discretionary trade by the Reporting Person.
2. This transaction was executed in multiple trades at prices ranging from $2.7010 to $2.7250. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request, to the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
Remarks:
/s/ Gilmore O'Neill06/05/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Editas Medicine (EDIT) CEO report in this Form 4 filing?

The CEO reported selling 15,380 shares of Editas Medicine common stock. The sale was tied to tax withholding for vested restricted stock units and executed under a pre-arranged automatic sales instruction plan rather than a discretionary trade.

How many Editas Medicine (EDIT) shares did the CEO sell and at what price?

He sold 15,380 shares of common stock at a weighted average price of $2.7011 per share. The transaction was executed in multiple trades within a narrow price range between $2.7010 and $2.7250, according to the filing footnote.

How many Editas Medicine (EDIT) shares does the CEO hold after this transaction?

Following the reported sale, the CEO directly holds 248,313 shares of Editas Medicine common stock. This figure reflects his remaining position after the 15,380 shares were sold to satisfy tax withholding obligations related to restricted stock unit vesting.

Was the Editas Medicine (EDIT) CEO’s share sale a discretionary trade?

No, the filing states the sale did not represent a discretionary trade by the CEO. It was executed under a durable automatic sales instruction plan and was necessary to meet tax withholding obligations arising from restricted stock units that vested on June 2, 2026.

Why did the Editas Medicine (EDIT) CEO sell shares in this transaction?

The sale was made to satisfy tax withholding obligations triggered by the vesting of restricted stock units on June 2, 2026. The filing explains the transaction occurred pursuant to an automatic sales instruction plan established on April 13, 2022, rather than a new trading decision.

How was the sale price for the Editas Medicine (EDIT) CEO’s shares determined?

The transaction was executed in multiple trades with prices ranging from $2.7010 to $2.7250 per share. The Form 4 reports a weighted average price of $2.7011, and the CEO has undertaken to provide full trade details upon request to regulators or shareholders.